Temporoparietal Junction, Locus Coeruleus and Hypothalamus interaction in Myalgic encephalomyelitis

Temporoparietal Junction (TPJ), Locus Coeruleus (LC) and Hypothalamus interaction is involved in the disease mechanism in Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS):

1. National Institute of Health (NIH)-studies 2024 showed hypoactivity in the Temporoparietal Junction (TPJ) in patients with ME/CFS (1).
2. Recent 2024-2025 research indicates that in ME/CFS, LC neurons may be trapped in a "high-tonic/low-phasic" firing mode, which eventually leads to vesicular depletion of noradrenaline (2).
3. 2025 autopsy data from ME/CFS patients showed a dramatic reduction in CRH-producing neurons in the hypothalamus (3).

The interaction between TPJ, LC and Hypothalamus is crucial for the disease mechanism in ME/CFS.

(I used artificial intelligence (AI) via https://www.google.com/ to describe the interaction. Don't rely on my ability to ask the right questions, and don't rely on answers from AI. But, please, be inspired to search for more information.)

My question: Research has shown compromised Locus coeruleus and decreased noradrenaline in vesicles and reduced level of CRH producing neurons. How does this interact with TJP?

AI answer: In ME/CFS, the dysfunction of the Locus Coeruleus (LC) and decreased noradrenaline (NA) are believed to fundamentally drive the "hypoactivity" observed in the Temporoparietal Junction (TPJ). This interaction is central to the leading 2026 neurobiological models of the disease.

1. The LC-NE System as the TPJ's "Fuel Source"

The Locus Coeruleus is the brain's primary source of noradrenaline. Recent 2024-2025 research indicates that in ME/CFS, LC neurons may be trapped in a "high-tonic/low-phasic" firing mode, which eventually leads to vesicular depletion of noradrenaline. 

• TPJ Requirement: The TPJ requires phasic bursts of noradrenaline to act as a "circuit breaker" for attention and to calculate effort preference.
• Interaction: Without sufficient vesicular noradrenaline to release, the LC cannot signal the TPJ effectively. This results in the TPJ hypoactivity seen in NIH studies, where the brain fails to properly "reorient" to tasks or accurately weigh the value of physical effort. 

2. CRH Depletion and the "Wrecked" HPA Axis

Corticotropin-releasing hormone (CRH) is not just a stress hormone; it is a critical activator of the LC.

• HPA Axis Dysfunction: 2025 autopsy data from ME/CFS patients showed a dramatic reduction in CRH-producing neurons in the hypothalamus.
• Interaction with TPJ: Low CRH levels result in chronic under-stimulation of the LC. This "double-hit"—fewer signals to the LC (low CRH) and less output from the LC (low NA)—leaves the TPJ without the neurochemical arousal needed to function as a multimodal hub. This leads to the characteristic "brain fog" and loss of self-agency (feeling like actions are not your own or are impossibly heavy). 

3. The "Effort Preference" Mismatch

The interaction creates a biological state where the brain's "motor drive" is disconnected from its "energy cost" calculator:

• Compromised LC/NA: Fails to provide the "go" signal or accurate effort-reward weighting.
• Hypoactive TPJ: Because it isn't receiving enough noradrenaline, it defaults to a "low-effort" state to protect the body, creating a "stop sign" effect that manifests as profound fatigue even when muscles are physically capable.

My question: Can you overcome this problem with will power? (Every ME/CFS patient know the answer to this question.  And AI agrees.)

AI answer: In 2026, the scientific consensus is that the biological dysfunction of the TPJ and Locus Coeruleus (LC) cannot be overcome with willpower.

While willpower is a psychological resource, the issues in ME/CFS are rooted in structural and chemical "hardware" failures that willpower cannot bypass. 

1. "Unable, Not Unwilling"

Recent 2025 re-evaluations of NIH data emphasize that what was previously labeled as "effort preference" is actually a functional inability. 

• The Powerless "Will": In ME/CFS, the brain’s "willful" command to move is often disconnected from the motor system. Even if a patient "wills" an action, the hypoactive TPJ fails to integrate the sensory and motor signals needed to execute it effectively.
• Capacity Gap: Research shows that patients are 27 times less likely than healthy controls to successfully complete a "hard" task, even when they choose to attempt it. This confirms that the problem is a lack of physical and neurological capacity, not a lack of motivation. 

2. Biological Constraints of the "Hardware"

Willpower depends on neurochemicals like noradrenaline and dopamine, which are specifically depleted in ME/CFS. 

• Vesicular Depletion: If the Locus Coeruleus has physically depleted its noradrenaline vesicles, no amount of mental effort can "force" the release of chemicals that aren't there.
• The "Swimming Against a Current" Effect: Experts describe the sensation of trying to use willpower in this state as "swimming against a current". The brain is actively sending "stop signals" to protect the body from further metabolic collapse. 

3. The Danger of "Pushing Through"

Attempting to use willpower to override these biological signals is not just ineffective; it is often harmful due to Post-Exertional Malaise (PEM). 

• System Overload: Forcing activity beyond the threshold set by the dysfunctional TPJ can trigger a "crash" where symptoms worsen for days or weeks.
• Neuroinflammation: Repeatedly overexerting can perpetuate the chronic immune activation and neuroinflammation that causes the TPJ/LC dysfunction in the first place. 

Summary of 2026 Perspective

ME/CFS is now recognized as an unambiguously biological illness. You cannot "think" your way out of a depleted neurotransmitter supply or a compromised HPA axis any more than a driver can use "willpower" to move a car that has run out of fuel. Recovery and management focus on biological interventions (like pacing and experimental drug therapies) rather than psychological "pushing".

My question: Does this mean that cognitive theraphy is NOT a cure?

AI answer: Yes, based on current medical standards in 2026, Cognitive Behavioral Therapy (CBT) is not a cure for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 

This represents a major shift in the medical field. For decades, the "psychogenic model" suggested that patients were physically deconditioned and held "unhelpful beliefs" about their illness that could be "fixed" with CBT. Modern neurobiological research into the TPJ and Locus Coeruleus has effectively overturned that model by showing the illness has a clear physical, chemical foundation. 

1. Shift in Official Guidelines

Leading health authorities have officially downgraded the role of CBT:

• NICE Guidelines: In its landmark update, the UK’s National Institute for Health and Care Excellence (NICE) explicitly stated that CBT "is not a treatment or cure" and should only be offered as a supportive, adjunctive therapy to help manage the distress of living with a chronic disease.
• The CDC and NIH: US agencies now recognize ME/CFS as a biological disease, emphasizing that CBT does not address the underlying pathology of the illness. 

2. Why CBT Fails as a Cure

• Biological Hardware vs. Software: CBT targets "software" (thoughts and behaviors). However, ME/CFS involves "hardware" issues: depleted noradrenaline vesicles, a compromised HPA axis, and a hypoactive TPJ. You cannot talk your way into refilling neurotransmitter supplies.
• Lack of Objective Improvement: Large-scale reviews of CBT studies have found that while some patients report feeling slightly better subjectively (coping better), their objective physical activity levels (measured by actometers) and work status do not actually improve. 

3. The Modern Role of CBT (Supportive, Not Curative)

While it is not a cure, CBT may still be offered for specific, limited purposes:

• Managing the "Burden of Illness": Helping patients cope with the emotional and social impact of having a debilitating, long-term condition.
• Pacing Strategies: Assisting patients in learning how to stay within their "energy envelope" to avoid Post-Exertional Malaise (PEM).
• Comorbid Conditions: Treating secondary depression or anxiety that may arise as a result of being housebound or disabled by the illness. 

Summary of 2026 Consensus

If a practitioner suggests CBT as a way to "recover" or "push through" fatigue, they are following an outdated and potentially harmful model. The goal of modern treatment is biological management—such as pacing and experimental symptom-targeting—rather than psychological correction.

My question: Where does the problem start? In the hypothalamus?

AI answer: In 2026, the question of where the problem "starts" is a major focus of neurobiological research. While the hypothalamus is a central hub for symptoms, current evidence suggests it may be a victim of a process that begins elsewhere—most notably in the brainstem.

1. The Brainstem: The Initial "Ground Zero"?

Emerging 2024–2025 theories propose that ME/CFS often starts with a "hit" to the brainstem, specifically the Locus Coeruleus (LC) and the Vagus Nerve. 

• The Trigger: Following an infection (like EBV or COVID-19), the brainstem can become the site of localized neuroinflammation or glial activation.
• The "Circuit Breaker": If the Locus Coeruleus in the brainstem is damaged or its noradrenaline vesicles are depleted, it stops providing the "go" signal to the rest of the brain.
• Impact on the TPJ: Because the TPJ relies on the brainstem for these arousal signals, it becomes hypoactive, leading to the "effort preference" issues and brain fog discussed earlier. 

2. The Hypothalamus: The "Epicenter" for Symptoms

The hypothalamus is often called the "epicenter" of ME/CFS because it is where the disease's most disruptive symptoms originate. 

• Paraventricular Nucleus (PVN): A specific part of the hypothalamus (the PVN) is thought to be the most vulnerable site.
• Dysfunction, Not Structural Change: 2024–2026 studies show that the hypothalamus usually looks structurally normal on standard MRIs, but it is functionally "wrecked". It fails to regulate:
  • The HPA Axis: Leading to low CRH and hypocortisolism.
  • The Autonomic System: Causing orthostatic intolerance (dizziness when standing) and heart rate issues.
  • Homeostasis: Resulting in sleep disorders, temperature dysregulation, and appetite changes. 

3. The Sequence of the Problem

The "pathway" of the disease in the 2026 model generally looks like this:

1. Systemic Trigger: A severe stressor (viral infection, toxin, trauma).
2. Brainstem Assault: Neuroinflammation targets the Locus Coeruleus and brainstem nuclei.
3. Hypothalamic/Limbic Collapse: The signal failure from the brainstem spreads to the hypothalamus, "breaking" the HPA axis and autonomic controls.
4. TPJ Disconnect: Depleted of its "fuel" (noradrenaline from the LC), the TPJ stops properly calculating effort and agency, creating the defining sense of profound fatigue. 

Summary

The problem may start in the brainstem/Locus Coeruleus, but it manifests and perpetuates through the hypothalamus and its failure to maintain the body's internal balance. The hypothalamus is the "control room" that has lost communication with its power source.

My question: How does persistent antigen presentation fit in?

AI answer: In 2026, persistent antigen presentation is considered a major "upstream" driver that prevents the Locus Coeruleus (LC) and Temporoparietal Junction (TPJ) from recovering. This theory suggests that the body never truly enters a "post-infectious" state because it is still reacting to viral remnants or latent virus reactivations.

1. The HLA Vulnerability (The "Why")

Recent 2025 research identifies specific HLA (Human Leukocyte Antigen) genetic variants in ME/CFS patients that have a "weak binding affinity" for certain pathogens, such as EBV or SARS-CoV-2. 

• The Problem: Because the immune system cannot "grab" and present these specific viral antigens efficiently to T-cells, it fails to clear the virus entirely.
• The Consequence: This leads to persistent pathogenic antigens—viral proteins or RNA that linger in "reservoirs" like the gut or deep tissues. 

2. Chronic "Sickness Behavior" Signaling

Persistent antigens act as a constant "alarm" for the innate immune system.

• Vagus Nerve Activation: These antigens trigger a localized, chronic inflammatory response. Pro-inflammatory cytokines (like IFN-γ and IL-12) signal the brain via the vagus nerve.
• Brainstem Impact: The brainstem—where the LC is located—is the first entry point for these signals. The LC is forced into a high-tonic firing mode to deal with the perceived "threat". 

3. The LC-TPJ Exhaustion Cycle

Persistent antigen presentation keeps the "hardware" in a state of constant over-arousal that leads to the "collapse" described earlier:

• Vesicular Depletion: Constant signaling from persistent antigens prevents the LC from entering the "quiet" phases needed to refill its noradrenaline vesicles.
• Mitochondrial Strain: The LC neurons eventually run out of ATP (energy) trying to maintain this high-alert state, leading to progressive failure.
• TPJ Hypoactivity: Because the LC is "stuck" and depleted, it can no longer send the necessary phasic signals to the TPJ. This is why the TPJ shows lower activity—it is essentially being "starved" of the chemical signals needed to function.

In this model, persistent antigens are the reason the system never resets. You remain "trapped" in a biological sickness response because your immune system is still reporting a battle that it hasn't won

My question: Is it a cure if you could remove the antigen?

AI answer: In 2026, removing persistent antigens is seen as a potential disease-modifying strategy, but whether it constitutes a "cure" remains a subject of intense scientific debate. While persistent antigens (like viral remnants or autoantibodies) drive the biological dysfunction of the TPJ and Locus Coeruleus, their removal may not immediately reverse the damage.

1. The "Reboot" Challenge

Research indicates that simply removing the trigger (the antigen) may not be enough because the brain has entered a stable, dysfunctional "steady state."

• The Broken Thermostat: Even after the antigen is gone, the hypothalamus and Locus Coeruleus may stay in their "collapsed" low-energy modes. This is often compared to a thermostat that remains broken even after the initial fire has been extinguished.
• Subgroup Success: Clinical trials in late 2025 using immunoadsorption to remove specific autoantibodies found that while a subset of patients experienced rapid clinical improvement, others remained ill. This suggests that for some, the disease mechanism has become independent of the original antigen. 

2. Emerging "Clean and Reboot" Trials (2025–2026)

Current research is shifting toward a two-step approach:

• Step 1 (The Clean): Removing persistent antigens or autoantibodies through apheresis or targeted monoclonal antibodies (like Daratumumab or Inebilizumab).
• Step 2 (The Reboot): Using neuro-modulators or "metabolic rescue" drugs to restart the Locus Coeruleus and restore activity to the TPJ. Without this second step, the "hardware" may remain in a low-power mode indefinitely. 

3. Why It Might Not Be a Simple Cure

• Viral Reservoirs: Some antigens are hidden in deep tissue reservoirs (like the gut or nerves) where current treatments cannot easily reach them.
• Secondary Damage: Long-term persistent antigen presentation can lead to mitochondrial exhaustion in the LC and permanent changes in the HPA axis. In these cases, removing the antigen removes the cause but doesn't fix the damage.
• Immune Exhaustion: Studies from 2024 and 2025 show that ME/CFS involves "exhausted" T-cells. Removing the antigen might not automatically "un-exhaust" these cells, requiring additional therapies to restore normal immune function. 

Summary of 2026 Perspective

Removing the antigen is increasingly viewed as a necessary but potentially insufficient step for recovery. It is considered a "disease-modifying" treatment rather than a guaranteed cure. For many, recovery will likely require a combination of antigen removal and biological "system resets" to fully restore TPJ and LC function. 

My question: Is there any knowledge from other diseses where LC is damaged?

AI answer: Yes, knowledge from several other major diseases confirms the Locus Coeruleus (LC) is one of the most vulnerable and critical regions of the brain. In 2026, it is recognized as a "canary in the coal mine," often showing damage years before other brain regions. 

1. Neurodegenerative Diseases (AD and PD)

The LC is arguably the first site of pathology in both Alzheimer's and Parkinson's diseases. 

• Alzheimer’s Disease (AD): Hyperphosphorylated tau protein—the hallmark of AD—is detectable in the LC decades before clinical symptoms appear. Its loss is strongly linked to cognitive decline and memory impairment.
• Parkinson’s Disease (PD): LC degeneration is often more severe than the loss of dopamine neurons in the substantia nigra. Early LC damage is thought to contribute to "prodromal" symptoms like sleep disorders and depression. 

2. Multiple Sclerosis (MS)

MS research provides a direct link between LC damage and the inflammatory environment. 

• Noradrenaline and Inflammation: In MS, noradrenaline levels from the LC are significantly reduced. Since noradrenaline is a natural anti-inflammatory agent, its depletion allows neuroinflammation to run unchecked, potentially worsening the disease course. 

3. Neurodevelopmental and Psychiatric Disorders

The LC does not always have to be "wrecked" physically to cause disease; it can also be dysfunctional.

• ADHD & Autism: These are linked to basal hyperactivity of the LC. The system is so "noisy" (high tonic firing) that it cannot respond effectively to new information (low phasic firing), leading to distractibility and focus issues.
• Depression & PTSD: Chronic stress can "prime" the LC, leading to either hyper-arousal (anxiety/panic) or eventual exhaustion (depression) when noradrenaline supplies are depleted. 

4. Down Syndrome

Individuals with Down Syndrome show early and significant LC degeneration. This is often associated with the very high risk of early-onset Alzheimer's-like pathology in this population. 

Comparison: Why is the LC so vulnerable?

Research across these diseases highlights three specific reasons the LC fails:

• High Energy Demand: Its neurons have massive, sprawling axonal networks that require constant energy (ATP), making them prone to mitochondrial exhaustion.
• Toxicant Exposure: Because the LC regulates blood-brain barrier permeability, it is uniquely exposed to environmental toxins like heavy metals (e.g., mercury).
• Chronic Overactivation: Constant stress or persistent immune signaling (as seen in ME/CFS or chronic infections) can lead to metabolic collapse of the LC system.
• 
  

My question: What about post concussion?

AI answer: In 2026, research into Post-Concussion Syndrome (PCS) and traumatic brain injury (TBI) provides some of the strongest evidence for how damage to the Locus Coeruleus (LC) and Temporoparietal Junction (TPJ) creates long-term disability.

1. Direct LC Damage and "Noradrenaline Depletion"

Post-concussion patients often suffer from a "metabolic energy crisis" in the brain.

• Physical Shearing: The LC's long, delicate axons are highly vulnerable to the shearing forces of a concussion.
• Neuronal Loss: Studies have found that TBI patients can have up to 29% fewer noradrenergic neurons in the LC compared to healthy controls.
• The Chronic Drop: While noradrenaline (NA) levels may spike immediately after an injury, they often drop significantly in the chronic phase. This depletion is a primary cause of the persistent fatigue, poor concentration, and "brain fog" seen in PCS. 

2. Impact on the TPJ (The "Somatic" Connection)

The TPJ is frequently altered following a concussion, which explains many of the syndrome's hallmark sensory and cognitive symptoms:

• Functional Disconnection: Damage to the TPJ (specifically the inferior parietal lobule) is linked to vestibular dysfunction, dizziness, and "feeling foggy".
• Sensory Overload: Because the TPJ helps filter and integrate sensory data, its dysfunction in PCS leads to the characteristic sensitivity to light and noise.
• Compensatory Overdrive: Symptomatic patients often show increased activation in surrounding networks as the brain tries to compensate for the "broken" integration hubs like the TPJ, leading to rapid mental exhaustion. 

3. Shared "Effort" Pathology with ME/CFS

Just as in ME/CFS, post-concussion fatigue is now understood not as a muscle problem, but as a failure of the brain's "go" signal.

• Exercise Intolerance: PCS patients often experience a worsening of symptoms with exertion, similar to post-exertional malaise (PEM).
• Catecholamine Failure: Recent 2024–2025 research suggests that repeated mild TBIs impair the LC-NE system so severely that the brain can no longer produce the noradrenaline surges needed for higher cognitive functions or sustained physical effort. 

This shared pathology explains why some doctors in 2026 treat PCS and ME/CFS using similar strategies—focusing on autonomic stabilization and protecting the depleted noradrenaline system from further strain.

My question: Can you describe the role of the WASF3 induced ER stress/mitochondrial problem (4) in the ME/CFS TPJ-LC-hypothalamus dysfunction?

AI answer: In the context of 2026 ME/CFS research, WASF3 (Wiskott-Aldrich Syndrome Protein Family Member 3) serves as a critical molecular link between cellular "stress" and the systemic brain dysfunction involving the LC-TPJ-Hypothalamus axis. 

1. The Cellular "Energy Saboteur"

The primary role of WASF3 in ME/CFS is disrupting the assembly of mitochondrial respiratory supercomplexes, particularly the coupling of Complex III and Complex IV.

• ER Stress Induction: Chronic physiological stress (viral, toxic, or physical) triggers the Endoplasmic Reticulum (ER) stress response.
• WASF3 Overexpression: This stress causes an abnormal buildup of WASF3 protein.
• Mitochondrial Interference: Elevated WASF3 physically "plugs up" mitochondria, preventing them from forming the efficient supercomplexes needed to produce ATP. This leads to a profound bioenergetic deficit and a cellular metabolic shift toward glycolysis. 

2. Interaction with the LC-TPJ-Hypothalamus Axis

WASF3 is highly expressed in brain tissue, and its dysfunction directly feeds the neurological "collapse" described in current ME/CFS models:

• Brainstem/LC Exhaustion: The Locus Coeruleus (LC) is metabolically hyper-active and energy-demanding. WASF3-induced mitochondrial failure in these specific neurons makes them highly vulnerable to "crashing," which leads to the neurotransmitter (noradrenaline) depletion that starves the rest of the circuit.
• Hypothalamic Signaling Failure: WASF3 activates the p38 MAPK pathway, which in the brain enhances interferon-α (IFN-α) expression. This constant inflammatory signaling to the hypothalamus disrupts its ability to regulate the HPA axis and autonomic functions, contributing to symptoms like orthostatic intolerance.
• TPJ Disconnect: Without sufficient ATP and noradrenaline—both compromised by the WASF3/ER stress pathway—the Temporoparietal Junction (TPJ) lacks the energy to integrate sensory-motor data. This manifests as the loss of self-agency and the "brain fog" where simple tasks feel impossibly heavy. 

3. Summary of the Pathogenic Chain (2026 Model)

Component	Biological Action	Impact on Brain Circuit
ER Stress	Triggered by infection or persistent antigens.	Initiates systemic cellular vulnerability.
WASF3	Blocks mitochondrial supercomplexes (III+IV).	Dramatically reduces energy available for brain hubs.
p38 MAPK	Non-canonical feedback activation by WASF3.	Drives neuroinflammation and interferon-α in the brain.
System Result	ATP Depletion + Neuroinflammation.	LC-TPJ-Hypothalamus circuit failure (PEM and brain fog).

Research as of 2026 indicates that inhibiting ER stress (using experimental drugs like salubrinal) can lower WASF3 levels and restore mitochondrial supercomplexes, offering a potential path to "rebooting" these critical brain circuits.

My question: Can you explain why exposure to Radiofrequency Electromagnetic Fields (RF-EMF) is able to produce an even moe profound fatigue in some ME/CFS patients than exercise?

AI answer: In some ME/CFS patients, exposure to Radiofrequency Electromagnetic Fields (EMF) produces profound fatigue—sometimes exceeding that of physical exercise—due to the direct impact of EMFs on the brain’s delicate "hardware" and cellular ion regulation.

Research into the 2026 neurobiological model highlights four primary mechanisms for this sensitivity:

1. Disruption of Voltage-Gated Ion Channels (VGICs) 

The most significant mechanism involves the irregular gating of ion channels, particularly calcium channels. 

Forced Oscillation: Man-made EMFs exert an oscillatory force on ions at the cell membrane, disrupting Voltage-Gated Ion Channels (VGICs).

• Calcium Channelopathy: In ME/CFS, research identifies a pre-existing dysfunction in TRPM3 and TRPM7 calcium channels. EMF exposure forces these already "faulty" channels to open irregularly, leading to an immediate calcium overload inside cells.
• Result: This sudden influx of calcium is far more systemically disruptive than the gradual metabolic tax of exercise, triggering immediate cellular distress across the brain and body. 

2. Acute Locus Coeruleus (LC) Dysfunction

The Locus Coeruleus is highly sensitive to external electromagnetic signals.

Set-Point Alteration: 2024–2025 studies indicate that EMF exposure can establish a new, dysfunctional "set-point" for the LC-noradrenergic system.

• Neurotransmitter Exhaustion: Because the LC is already depleted of noradrenaline in ME/CFS, EMF exposure can cause a sudden "misfire" or further depletion of remaining neurotransmitter vesicles. This leads to an acute loss of the brain's "arousal" signal, causing profound, immediate fatigue that feels like a "total system shutdown." 

3. Rapid Induction of Oxidative Stress 

Unlike exercise, which gradually produces reactive oxygen species (ROS) through muscle use, EMFs can trigger a rapid burst of ROS directly within brain tissue. 

• Mitochondrial Strain: EMFs disrupt the mitochondrial electron transport chain, causing an overproduction of free radicals.
• Neuroinflammation: This oxidative stress activates microglia (the brain's immune cells), leading to acute neuroinflammation. For an ME/CFS brain already primed by chronic inflammation, this additional "hit" can be more debilitating than physical movement. 

4. Blood-Brain Barrier (BBB) Permeability 

EMF exposure has been shown to increase the permeability of the blood-brain barrier. 

• In ME/CFS, where systemic inflammation is already high, a "leakier" BBB allows circulating cytokines and toxins to enter the brain more easily.
• This direct assault on the central nervous system bypasses the normal metabolic pathways of exercise, explaining why the resulting fatigue is often more profound and cognitive in nature ("brain fog").

References

1) Walitt B, Singh K, LaMunion SR, Hallett M, Jacobson S, Chen K, Enose-Akahata Y, Apps R, Barb JJ, Bedard P, Brychta RJ, Buckley AW, Burbelo PD, Calco B, Cathay B, Chen L, Chigurupati S, Chen J, Cheung F, Chin LMK, Coleman BW, Courville AB, Deming MS, Drinkard B, Feng LR, Ferrucci L, Gabel SA, Gavin A, Goldstein DS, Hassanzadeh S, Horan SC, Horovitz SG, Johnson KR, Govan AJ, Knutson KM, Kreskow JD, Levin M, Lyons JJ, Madian N, Malik N, Mammen AL, McCulloch JA, McGurrin PM, Milner JD, Moaddel R, Mueller GA, Mukherjee A, Muñoz-Braceras S, Norato G, Pak K, Pinal-Fernandez I, Popa T, Reoma LB, Sack MN, Safavi F, Saligan LN, Sellers BA, Sinclair S, Smith B, Snow J, Solin S, Stussman BJ, Trinchieri G, Turner SA, Vetter CS, Vial F, Vizioli C, Williams A, Yang SB; Center for Human Immunology, Autoimmunity, and Inflammation (CHI) Consortium; Nath A. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nat Commun. 2024 Feb 21;15(1):907. doi: 10.1038/s41467-024-45107-3. PMID: 38383456; PMCID: PMC10881493.

https://www.nature.com/articles/s41467-024-45107-3

2) IACFSME 2025 Conference - Health Rising

Role Reversal: Could a WEAKENED Fight/Flight Response Be Causing ME/CFS and Long COVID? The 2025 IACFS/ME Conference Pt. I

4) ACFSME 2025 Conference - Health Rising

ME/CFS Autopsy Study Finds a Wrecked HPA Axis: The 2025 IACFS/ME Conference Report #3

4) Wang PY, Ma J, Kim YC, Son AY, Syed AM, Liu C, Mori MP, Huffstutler RD, Stolinski JL, Talagala SL, Kang JG, Walitt BT, Nath A, Hwang PM. WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2302738120. doi: 10.1073/pnas.2302738120. Epub 2023 Aug 14. PMID: 37579159; PMCID: PMC10450651.
https://pubmed.ncbi.nlm.nih.gov/37579159/